Information on the Total Number of Voting Rights (Denominator) following conversion notices from NEGMA
22 Février 2022 - 8:01AM
Information on the Total Number of Voting Rights (Denominator)
following conversion notices from NEGMA
Negma Group has converted 200 convertible bonds in
Oxurion resulting in a EUR 500,000 capital increase. This is part
of Negma Group’s EUR 30 million Capital Commitment1 that will allow
Oxurion to focus on progressing its novel and differentiated back
of the eye drug candidates that are targeting potential market
opportunities of over USD 12 billion.
Leuven, BE, Boston, MA,
US – February
22,
2022 –
08.00
AM CET – In accordance with
article 15 of the Belgian Act of May 2, 2007 on the disclosure of
major participations in issuers of which shares are admitted to
trading on a regulated market and regarding miscellaneous
provisions, Oxurion NV (Euronext Brussels: OXUR) (the “Company” or
“Oxurion”), announces the below information, following the issuance
of 335,569 new ordinary shares on February 8 (as listed on February
15), 2022, for a total amount of EUR 500,000 (including an issue
premium amounting to EUR 16,780.64), as the result of the
conversion of 200 convertible bonds pursuant to the Capital
Commitment entered into with Negma Group.
Following completion of the capital increase,
the total number of shares issued by Oxurion amounts to 39,402,853
outstanding ordinary shares carrying voting rights (compared to
39,067,284 outstanding ordinary shares previously). This number
will be used as the denominator for the calculation of the
percentages of shareholdings.
Therefore, Oxurion publishes the following
updated information:
|
56,925,661.32 |
- Total number of securities with
voting rights (all ordinary shares)
|
39,402,853 |
- Total number of ordinary shares (=
denominator)
|
39,402,853 |
- Number of outstanding rights to
subscribe to securities carrying voting rights not yet issued:
|
|
- 760,750 subscription rights
(“SR’s”) issued on November 20, 2017, entitling their holders to
subscribe to a total number of 760,750 securities carrying voting
rights (all ordinary shares);
- 135,000 SR’s issued on December 23,
2020, entitling their holders to subscribe to a total number of
135,000 securities carrying voting rights (all ordinary
shares);
- 1,039,500 SR’s issued on April 14,
2021, entitling their holders to subscribe to a total number of
1,039,500 securities carrying voting rights (all ordinary
shares);
- 550,000 SR’s issued on September
22, 2021, entitling their holders to subscribe to a total number of
550,000 securities carrying voting rights (all ordinary
shares);
- 470 convertible bonds issued on
October 11, 2021, entitling their holder (Negma Group) to subscribe
to a total number of securities carrying voting rights (all
ordinary shares) in accordance with the terms and conditions set
forth in the Issuance and subscription agreement entered into
between the Company and Negma Group on August 26, 2021;
- 100 convertible bonds issued on
December 20, 2021, entitling their holders (Kreos Capital VI (UK)
Limited, Pontifax Medison Finance (Israel) L.P. and Pontifax
Medison Finance (Cayman) L.P.) to subscribe to a total number of
securities carrying voting rights (all ordinary shares) in
accordance with the terms and conditions of these convertible bonds
as attached to the Agreement for the provision of a Loan Facility
entered into between the Company, Kreos Capital VI (UK) Limited,
Pontifax Medison Finance (Israel) L.P. and Pontifax Medison Finance
(Cayman) L.P., on November 21, 2021; and
- 862,000 SR’s issued on December 30,
2021, entitling their holders to subscribe to a total number of
862,000 securities carrying voting rights (all ordinary
shares).
|
END
For further information please
contact:
Oxurion NV Tom GraneyChief Executive OfficerTel: +32 16 75
13 10tom.graney@oxurion.com Michaël DillenChief Business
OfficerTel: +32 479 783 583michael.dillen@oxurion.com |
EU MEDiSTRAVA ConsultingDavid Dible/Sylvie Berrebi/Frazer HallTel:
+44 203 928 6900oxurion@medistrava.com USWestwicke, an
ICR companyChristopher BrinzeyTel: +1 617 835
9304chris.brinzey@westwicke.com |
About Oxurion
Oxurion (Euronext Brussels: OXUR) is a
biopharmaceutical company developing next generation standard of
care ophthalmic therapies, which are designed to better preserve
vision in patients with retinal vascular disorders including
diabetic macular edema (DME), the leading cause of vision loss in
diabetic patients worldwide as well as other conditions, including
wet age-related macular degeneration (wet AMD) and macular edema
following retinal vein occlusion (ME-RVO).
Oxurion is aiming to build a leading global
franchise in the treatment of retinal vascular disorders based on
the successful development of its two novel therapeutics. THR-149
is a potent plasma kallikrein inhibitor being developed as a
potential new standard of care for the 40-50% of DME patients
showing suboptimal response to anti-VEGF therapy. THR-687 is a
highly selective pan-RGD integrin antagonist that is being
developed as a potential first line therapy for DME patients as
well as wet AMD and potentially ME-RVO. Oxurion is headquartered in
Leuven, Belgium, with corporate operations in Boston, MA. More
information is available at www.oxurion.com.
Important information about
forward-looking statements
Certain statements in this press release may be
considered “forward-looking”. Such forward-looking statements are
based on current expectations, and, accordingly, entail and are
influenced by various risks and uncertainties. The Company
therefore cannot provide any assurance that such forward-looking
statements will materialize and does not assume any obligation to
update or revise any forward-looking statement, whether as a result
of new information, future events, or any other reason. Additional
information concerning risks and uncertainties affecting the
business and other factors that could cause actual results to
differ materially from any forward-looking statement is contained
in the Company’s Annual Report. This press release does not
constitute an offer or invitation for the sale or purchase of
securities or assets of Oxurion in any jurisdiction. No
securities of Oxurion may be offered or sold within the United
States without registration under the U.S. Securities Act of 1933,
as amended, or in compliance with an exemption therefrom, and in
accordance with any applicable U.S. state securities laws.
1 Press release Oxurion, 06/04/2021
Oxurion NV (EU:OXUR)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024
Oxurion NV (EU:OXUR)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024